André Traunecker
Basel Institute for Immunology
28 Papers
1.5K Citations
André Traunecker is an academic researcher from Basel Institute for Immunology. The author has contributed to research in topics: T-cell receptor & T cell. The author has an hindex of 21, co-authored 28 publications.
Chat about Author
Papers
Soluble CD4 molecules neutralize human immunodeficiency virus type 1.
TL;DR: Recombinant DNA techniques are used to generate soluble forms of CD4, and it is shown that these are potent inhibitors of HIV infection in vitro.
473
Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells.
TL;DR: A novel design of sCD4 molecules which exploit cytotoxic T cells as their effector function are described which induce killing of HIV‐1 infected cells.
464
Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules
TL;DR: The generation of molecules which combine the specificity of CD4 and the effector functions of different immunoglobulin subclasses are described and it is found that the pentameric CD4–IgM chimaera is at least 1,000-fold more active than its dimeric CD4.–IgG counterpart in syncytiurm inhibition assays.
322
The role of DNA rearrangement and alternative RNA processing in the expression of immunoglobulin delta genes
Richard A. Maki,William Roeder,André Traunecker,Charles L. Sidman,Matthias Wabl,William C. Raschke,Susumu Tonegawa +6 more
TL;DR: Results of Southern gel blot analysis and gene cloning experiments indicate that this cell utilizes the same rearranged VH gene for the synthesis of the mu and delta chains, and yet maintains the embryonic configuration for the C mu and C delta genes and for the intervening region.
258
Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor.
TL;DR: The soluble TCR is biologically active: it specifically inhibits antigen-dependent activation of the relevant T-cell clones and thus discriminates between proper and irrelevant peptides presented by major histocompatibility complex molecules.
246